ORPHA:79443
Pseudohypoparathyroidism type 1A
Also known as: AHO-PHP syndrome Ia · Albright hereditary osteodystrophy-PHP syndrome Ia
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
13,002
Trials
6
Interventional, condition-specific
Researchers
1,011
Distinct authors in sample
Gene link
GNAS
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
Pseudohypoparathyroidism type 1A (PHP1a) is a type of pseudohypoparathyroidism (PHP) characterized by renal resistance to parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, and elevated PTH; resistance to other hormones including thydroid stimulating hormone (TSH), gonadotropins and growth-hormone-releasing hormone (GHRH); and a constellation of clinical features known as Albright osteodystrophy (AHO).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007078
- MeSH:C537045
- OMIM:103580
- UMLS:C3494506
- NCIT:C129721
Additional Mondo synonyms (4)
Albright hereditary osteodystrophy · Albright hereditary osteodystrophy with multiple hormone resistance · PHP1A · Pseudohypoparathyroidism Ia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — GNAS
- LiteraturePresent
13,002 matched papers (8,990 in last 10 years) Source
- Phenotype characterisedPresent
98 HPO annotations (e.g. Low urinary cyclic AMP response to PTH administration; Delayed eruption of teeth; Brachydactyly) Source
- Animal modelPresent
4 genotype models (Danio rerio, Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
6 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GNAS).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
98
Associated phenotypes · MONDO:0007078
- Low urinary cyclic AMP response to PTH administration
- Delayed eruption of teeth
- Brachydactyly
- Short stature
- Thickened calvaria
Showing 5 of 98 — open Monarch for the full list.
Animal models (Monarch / Alliance)
4
Model associations linked to this Mondo ID
- AB + MO1-gnas + MO2-gnas·ZFIN:ZDB-FISH-250416-1·Danio rerio
- Pthlhtm1Hmk/Pthlhtm1Hmk [background:] either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * C57BL/6)·MGI:3583956·Mus musculus
- Gnastm4Lsw/Gnas+ [background:] involves: 129S6/SvEvTac·MGI:5818292·Mus musculus
- Gnastm1Gwa/Gnas+ [background:] involves: 129S/SvEv * 129S4/SvJae·MGI:5285183·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0007078
- THEOPHYLLINE·phase 2
- SOMATROPIN·unknown
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
13,002
13,002 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
13,002 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,990 in the last 10 years · low confidence
Phrase hits: 2,359 · MeSH hits: 0
Who's working on it?
1,011
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Linglart A8 papers · 2026
Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, AP-HP, Bicêtre Paris-Saclay University Hospital, 94270 Le Kremlin-Bicêtre, France.
Papers in Europe PMC - 02Li M7 papers · 2026
Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University , ,
Papers in Europe PMC - 03Berkenou J6 papers · 2026
Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, AP-HP, Filière OSCAR and Platform of expertise for rare diseases Paris-Saclay, Bicêtre Paris-Saclay Hospital, 94270 Le Kremlin-Bicêtre, France.
Papers in Europe PMC - 04Del Sindaco G6 papers · 2026
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Papers in Europe PMC - 05Mantovani G6 papers · 2026
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Papers in Europe PMC - 06Pagnano A6 papers · 2026
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Papers in Europe PMC - 07Rothenbuhler A6 papers · 2026
Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, AP-HP, Bicêtre Paris-Saclay University Hospital, 94270 Le Kremlin-Bicêtre, France.
Papers in Europe PMC - 08Chen X4 papers · 2026
Department of Endocrinology, Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China. onlycx@163.com.
Papers in Europe PMC - 09Jüppner H4 papers · 2025
Department of Medicine, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.
Papers in Europe PMC - 10Kagami M4 papers · 2026
Department of Molecular Endocrinology, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 2 trials are registered for pseudohypoparathyroidism, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
6 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.1th percentile).
low confidence · 90.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04240821·ENROLLING BY INVITATION·Theophylline for Treatment of Pseudohypoparathyroidism
Not reviewed·Conditions: Pseudohypoparathyroidism · Pseudohypoparathyroidism Type 1a · Albright Hereditary Osteodystrophy·Matched via name phrase
- NCT07496463·ENROLLING BY INVITATION·Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Not reviewed·Conditions: Pseudohypoparathyroidism Type 1a · Obesity·Matched via name phrase
Broader category: pseudohypoparathyroidism
2
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03718403·RECRUITING·Effect of Theophylline in Pseudohypoparathyroidism
Not reviewed·Conditions: PHP Ia · PHP IB · Php1C·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pseudohypoparathyroidism type 1A — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Pseudohypoparathyroidism type 1A" OR "AHO-PHP syndrome Ia" OR "Albright hereditary osteodystrophy-PHP syndrome Ia" OR "Albright hereditary osteodystrophy" OR "Albright hereditary osteodystrophy with multiple hormone resistance" OR "PHP1A" OR "Pseudohypoparathyroidism Ia") OR (MESH:"[OBSOLETE] Albright's hereditary osteodystrophy") OR ("GNAS" OR "GNAS syndrome" OR "GNAS-related")MeSH descriptor terms unioned into the query: [OBSOLETE] Albright's hereditary osteodystrophy
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pseudohypoparathyroidism type 1A" OR "AHO-PHP syndrome Ia" OR "Albright hereditary osteodystrophy-PHP syndrome Ia" OR "Albright hereditary osteodystrophy" OR "Albright hereditary osteodystrophy with multiple hormone resistance" OR "PHP1A" OR "Pseudohypoparathyroidism Ia" OR "[OBSOLETE] Albright's hereditary osteodystrophy"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pseudohypoparathyroidism"
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- "Albright hereditary osteodystrophy" also appears on ORPHA:665
- Publication count (13002) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T02:25:38.269Z
